{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T02:48:12Z","timestamp":1787194092156,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T00:00:00Z","timestamp":1447718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T00:00:00Z","timestamp":1447718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/pcan.2015.53","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T11:21:45Z","timestamp":1447759305000},"page":"72-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"19","author":[{"given":"B A","family":"Teply","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Luber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Denmeade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E S","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,17]]},"reference":[{"key":"BFpcan201553_CR1","first-page":"CD010756","volume":"4","author":"A Haywood","year":"2015","unstructured":"Haywood A, Good P, Khan S, Leupp A, Jenkins-Marsh S, Rickett K et al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev 2015; 4: CD010756.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFpcan201553_CR2","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","volume":"31","author":"S Yennurajalingam","year":"2013","unstructured":"Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013; 31: 3076\u20133082.","journal-title":"J Clin Oncol"},{"key":"BFpcan201553_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/annonc\/mds216","volume":"24","author":"TB Dorff","year":"2013","unstructured":"Dorff TB, Crawford ED . Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 2013; 24: 31\u201338.","journal-title":"Ann Oncol"},{"key":"BFpcan201553_CR4","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2014.531","volume":"111","author":"D Lorente","year":"2014","unstructured":"Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014; 111: 2248\u20132253.","journal-title":"Br J Cancer"},{"key":"BFpcan201553_CR5","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756\u20131764.","journal-title":"J Clin Oncol"},{"key":"BFpcan201553_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502\u20131512.","journal-title":"New Engl J Med"},{"key":"BFpcan201553_CR7","doi-asserted-by":"publisher","first-page":"8147","DOI":"10.1158\/1078-0432.CCR-04-1402","volume":"10","author":"R Dagher","year":"2004","unstructured":"Dagher R, Ning L, Abraham S, Rahman A, Sridhara R, Pazdur R . Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 8147\u20138151.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201553_CR8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513\u20131520.","journal-title":"N Engl J Med"},{"key":"BFpcan201553_CR9","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1200\/JCO.2008.16.9524","volume":"26","author":"JP Machiels","year":"2008","unstructured":"Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26: 5261\u20135268.","journal-title":"J Clin Oncol"},{"key":"BFpcan201553_CR10","first-page":"307","volume":"6","author":"MH Lafeuille","year":"2013","unstructured":"Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS . Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases. Am Health Drug Benefits 2013; 6: 307\u2013316.","journal-title":"Am Health Drug Benefits"},{"key":"BFpcan201553_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","volume":"19","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD . Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 2014; 19: 1231\u20131240.","journal-title":"Oncologist"},{"key":"BFpcan201553_CR12","first-page":"8712","volume":"61","author":"CY Chang","year":"2001","unstructured":"Chang CY, Walther PJ, McDonnell DP . Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 2001; 61: 8712\u20138717.","journal-title":"Cancer Res"},{"key":"BFpcan201553_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcb.10757","volume":"91","author":"H Miyamoto","year":"2004","unstructured":"Miyamoto H, Rahman MM, Chang CS . Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 91: 3\u201312.","journal-title":"J Cell Biochem"},{"key":"BFpcan201553_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33\u201339.","journal-title":"Nat Med"},{"key":"BFpcan201553_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","volume":"6","author":"XY Zhao","year":"2000","unstructured":"Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703\u2013706.","journal-title":"Nat Med"},{"key":"BFpcan201553_CR16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/endo.143.5.8778","volume":"143","author":"AV Krishnan","year":"2002","unstructured":"Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 2002; 143: 1889\u20131900.","journal-title":"Endocrinology"},{"key":"BFpcan201553_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-014-0320-6","volume":"16","author":"C Ndibe","year":"2015","unstructured":"Ndibe C, Wang CG, Sonpavde G . Corticosteroids in the management of prostate cancer: a critical review. Curr Treat Options Oncol 2015; 16: 6.","journal-title":"Curr Treat Options Oncol"},{"key":"BFpcan201553_CR18","first-page":"5001","volume":"33","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR et al. Docetaxel and\/or zoledronic acid for hormone-naive prostate cancer: first overall survival results from STAMPEDE (NCT00268476). ASCO Meeting Abstr 2015; 33: 5001.","journal-title":"ASCO Meeting Abstr"},{"key":"BFpcan201553_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737\u2013746.","journal-title":"N Engl J Med"},{"key":"BFpcan201553_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008; 26: 1148\u20131159.","journal-title":"J Clin Oncol"},{"key":"BFpcan201553_CR21","doi-asserted-by":"publisher","first-page":"10601","DOI":"10.1007\/s13277-014-2559-8","volume":"35","author":"E Francini","year":"2014","unstructured":"Francini E, Petrioli R, Rossi G, Laera L, Roviello G . PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumour Biol 2014; 35: 10601\u201310607.","journal-title":"Tumour Biol"},{"key":"BFpcan201553_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 2014; 371: 424\u2013433.","journal-title":"New Engl J Med"},{"key":"BFpcan201553_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.eururo.2013.08.007","volume":"66","author":"RJ van Soest","year":"2014","unstructured":"van Soest RJ, de Morree ES, Shen LJ, Tannock IF, Eisenberger MA, de Wit R . Initial biopsy gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol 2014; 66: 330\u2013336.","journal-title":"Eur Urol"},{"key":"BFpcan201553_CR24","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0022-5347(05)64163-8","volume":"168","author":"W Berry","year":"2002","unstructured":"Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L . Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439\u20132443.","journal-title":"J Urol"},{"key":"BFpcan201553_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 2013; 368: 138\u2013148.","journal-title":"New Engl J Med"},{"key":"BFpcan201553_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0090-4295(02)01741-7","volume":"60","author":"M Fakih","year":"2002","unstructured":"Fakih M, Johnson CS, Trump DL . Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002; 60: 553\u2013561.","journal-title":"Urology"},{"key":"BFpcan201553_CR27","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","volume":"70","author":"ML Zhu","year":"2010","unstructured":"Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70: 7992\u20138002.","journal-title":"Cancer Res"},{"key":"BFpcan201553_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","volume":"66","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 66: 646\u2013652.","journal-title":"Eur Urol"},{"key":"BFpcan201553_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocr Metab 2012; 97: 507\u2013516.","journal-title":"J Clin Endocr Metab"},{"key":"BFpcan201553_CR30","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-13-2134","volume":"19","author":"PG Kluetz","year":"2013","unstructured":"Kluetz PG, Ning YM, Maher VE, Zhang LJ, Tang SH, Ghosh D et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: US Food and Drug Administration Drug approval summary. Clin Cancer Res 2013; 19: 6650\u20136656.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201553_CR31","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995\u20132005.","journal-title":"New Engl J Med"},{"key":"BFpcan201553_CR32","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/jcb.24464","volume":"114","author":"JJ Kim","year":"2013","unstructured":"Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem 2013; 114: 1286\u20131293.","journal-title":"J Cell Biochem"},{"key":"BFpcan201553_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4161\/cc.11.2.18945","volume":"11","author":"A Yemelyanov","year":"2012","unstructured":"Yemelyanov A, Bhalla P, Yang XM, Ugolkov A, Iwadate K, Karseladze A et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle 2012; 11: 395\u2013406.","journal-title":"Cell Cycle"},{"key":"BFpcan201553_CR34","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu CX, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 2014; 371: 1028\u20131038.","journal-title":"New Engl J Med"},{"key":"BFpcan201553_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","volume":"33","author":"HI Scher","year":"2015","unstructured":"Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia XY et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 1348.","journal-title":"J Clin Oncol"},{"key":"BFpcan201553_CR36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309\u20131322.","journal-title":"Cell"},{"key":"BFpcan201553_CR37","first-page":"6","volume":"31","author":"HI Scher","year":"2013","unstructured":"Scher HI, Fizazi K, Saad F, Chi KN, Taplin M-E, Sternberg CN et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. ASCO Meeting Abstr 2013; 31: 6.","journal-title":"ASCO Meeting Abstr"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201553","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:05:03Z","timestamp":1648674303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFpcan201553"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2015.53","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,17]]},"assertion":[{"value":"7 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}